Abemaciclib 150 MG Oral Tablet

DRUG2 trials

Sponsors

University of Michigan Rogel Cancer Center, Nagoya City University

Conditions

Breast CancerCYP3A4*22ctDNA Monitoring

Phase 2

Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer

Not yet recruitingNCT07292207

Nagoya City UniversityBreast Cancer, ctDNA Monitoring

Start: 2026-01-10End: 2031-08-31Target: 30Updated: 2025-12-18

Phase 4

Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype

WithdrawnNCT05691400

University of Michigan Rogel Cancer CenterCYP3A4*22

Start: 2024-03-31End: 2027-03-31Updated: 2024-02-02